# Johnson & Johnson Stock Analysis: Moderate Buy Rating & Growth Prospects
Dive into our comprehensive analysis of Johnson & Johnson (J&J) stock, currently trading at $155.20 per share with a substantial market cap of $375 billion. Discover why analysts maintain a "moderate buy" consensus despite mixed price targets, with Goldman Sachs recently upgrading to "buy" while others like Leerink Partners have become more cautious. Learn about J&J's impressive quarterly performance, exceeding expectations with $2.77 EPS and nearly $22 billion in revenue. Explore the company's strong fundamentals, including its attractive P/E ratio, low debt levels, and impressive 30%+ ROE. With a promising 3%+ dividend yield for 2025 and recent pharmaceutical innovations, find out why J&J continues to attract both income and growth investors despite current price consolidation. Perfect for investors seeking insights into blue-chip healthcare stocks with defensive qualities and long-term growth potential.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
